NOAH Compendium

Printed from NOAH Compendium ( (c) Copyright NOAH Compendium 2024. All Rights Reserved.
Date: Sunday, May 26, 2024 13:13

Description: Virbac 2013
Release 2.31
Endogard Flavour Plus Tablets for Dogs
Species: Dogs
Therapeutic indication: Pharmaceuticals: Endoparasiticides: Anthelmintics for dogs, Tapeworm products
Active ingredient: Febantel, Praziquantel, Pyrantel Embonate
Product:Endogard Flavour Plus Tablets for Dogs
Product index: Endogard Flavour Plus Tablets for Dogs
Qualitative and quantitative composition
Praziquantel 50 mg
Pyrantel embonate 144 mg
Febantel 150 mg
Pharmaceutical form
Round, yellow, uncoated tablets with visible darker spots and bevelled edges with cross line on one side and plain on other side.
The tablets can be divided into equal halves or equal quarters.
Clinical particulars
Target species
Dogs, small and medium sizes
Indications for use
For the treatment of mixed infestations with the following roundworms and tapeworms in adult dogs and puppies:
Ascarids: Toxocara canis, Toxascaris leonina (late immature forms and mature forms)
Hookworms: Uncinaria stenocephala, Ancylostoma caninum (adults)
Tapeworms: Taenia spp., Dipylidium caninum
Do not use simultaneously with piperazine compounds.
Do not exceed the stated dosage when treating pregnant bitches.
Do not use in animals with a known hypersensitivity to the active substance or to any of excipients.
Not for use in dogs younger than 2 weeks of age and/or weighing less than 2 kg.
Special warnings for each target species
Fleas serve as intermediate hosts for one common type of tapeworm – Dipylidium caninum. Tapeworm infestation is certain to re-occur unless control of intermediate hosts as fleas, mice etc is undertaken.
Special precautions for use
Special precautions for use in animals
Any part-used tablets should be discarded.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In the interests of good hygiene, persons administering the tablet directly to a dog or by adding it to the dog's food should wash their hands afterwards.
In case of accidental ingestion, seek medical advice and show the package leaflet to the physician.
Adverse reactions
In rare cases transient loose faeces, diarrhoea and/or vomiting may occur in some puppies. In adult dogs, very rare cases of vomiting, with or without diarrhoea, may occur.
Use during pregnancy, lactation or lay
Consult a veterinary surgeon before treating pregnant animals for roundworms.
The product may be used during lactation.
Do not use in bitches during the first two-thirds of pregnancy.
Do not use simultaneously with piperazine as the anthelmintic effects of pyrantel and piperazine (used in many worming products for dogs) may be antagonized.
Concurrent use with other cholinergic compounds can lead to toxicity.
Amounts to be administered and administration route
For oral administration.
The recommended dose rates are: 15 mg/kg bodyweight febantel, 14.4 mg/kg pyrantel and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 10 kg bodyweight.
Tablets may be halved/quartered to allow accuracy of dosing.
Administration and Duration of Treatment
The tablet(s) can be given directly to the dog or disguised in food. No restriction of access to food is required either before or after administration of the product.
To ensure administration of a correct dose, body weight should be determined as accurately as possible.
Puppies may be wormed with this product from 2 weeks of age and every 2 weeks until 12 weeks of age. Thereafter they should be treated at 3 monthly intervals. It is advisable to treat the bitch at the same time as the puppies.
For the control of Toxocara, nursing bitches should be dosed 2 weeks after giving birth and every 2 weeks until weaning.
For routine control a single dose is recommended at 3 monthly intervals.
In the event of a heavy roundworm infestation, a repeat dose should be given after 14 days.
Benzimidazoles possess wide safety margin. Pyrantel is not absorbed systematically to any extent. Praziquantel also has a wide safety margin, of up to five times the recommended dose.
Withdrawal periods
Not applicable
Pharmacological particulars
Pharmacotherapeutic group: Anthelmintics, Benzimidazoles and related substances
ATCvet code: QP52AC55
Pharmacodynamic properties
The product contains anthelmintics active against roundworms and tapeworms. The product contains three active substances: febantel, pyrantel embonate (pamoate) and praziquantel, a partially hydrogenated pyrazino-isoquinoline derivative used widely as an anthelmintic for both human and veterinary use. Pyrantel acts as a cholinergic agonist. Its mode of action is to stimulate nicotinic cholinergic receptors of the parasite, induce spastic paralysis and thereby allow removal from the gastro-intestinal (GI) system by peristalsis.
With the mammalian system febantel undergoes ring closure forming fenbendazole and oxfendazole. It is these chemical entities which exert the anthelmintic effect by inhibition of tubulin polymerization. Formation of microtubules is thereby prevented, resulting in disruption to structures vital to the normal functioning of the helminth. Glucose uptake, in particular, is affected, leading to depletion in cell ATP. The parasite dies upon exhaustion of its energy reserves, which occurs 2 – 3 days later.
Praziquantel is very rapidly absorbed and distributed throughout the parasite. Both in vitro and in vivo studies have shown that praziquantel causes severe damage to the parasite integument, resulting in contraction and paralysis. There is an almost instantaneous tetanic contraction of the parasite musculature and a rapid vacuolisation of the syncytial tegument. This rapid contraction has been explained by changes in divalent cation fluxes, especially calcium.
In this fixed combination product pyrantel and febantel act synergistically against all relevant nematodes (ascarids and hookworms) in dogs. In particular, the activity spectrum covers Toxocara canis, Toxascaris leonina, Uncinaria stenocephala and Ancylostoma caninum. The spectrum of activity of praziquntel covers also cestode species in dogs, in particular all Taenia spp.and Dipylidium caninum,. Praziquantel acts against adult and immature forms of these parasites.
Pharmacokinetic properties
Perorally administered praziquantel is absorbed almost completely from the intestinal tract. After absorption, the drug is distributed to all organs. Praziquantel is metabolized into inactive forms in the liver and secreted in bile. It is excreted within 24 hours to more than 95% of the administered dosage. Only traces of non-metabolised praziquantel are excreted.
The pamoate salt of pyrantel has low aqueous solubility, an attribute that reduces absorption from the gut and allows the drug to reach and be effective against parasites in the large intestine. Because of the low systemic absorption of pyrantel pamoate, there is very little danger of adverse reactions/toxicity in the host. Following absorption, pyrantel pamoate is quickly and almost completely metabolized into inactive metabolites that are excreted rapidly in the urine.
Febantel is absorbed relatively rapidly and metabolized to a number of metabolites including fenbendazole and oxfendazole, which have anthelmintic activity.
Pharmaceutical particulars
Lactose Monohydrate
Maize Starch
Povidone K-30
Sodium Lauryl Sulfate
Microcrystalline Cellulose
Colloidal Anhydrous Silica
Magnesium Stearate
Meat Flavour
Major incompatibilities
None known
Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.
Special precautions for storage
This medicinal product does not require any special storage conditions.
Immediate packaging
Print and perforated Alu-Alu blister: 100 tablets (10 blisters with 10 tablets), in a box.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Marketing Authorisation Holder (if different from distributor)
KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Marketing Authorisation Number
Vm 01656/4017
Significant changes
Date of the first authorisation or date of renewal
June 2011
Date of revision of the text
July 2020
Any other information
Legal category
Legal category: NFA-VPS